Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | TRT skin-graft study accepted for publication in the Journal of the American College of SurgeonsStudy investigating the effects of SoftWaves on skin graft sites finds reduced mean epithelization times after single treatment.
The study, titled “Prospective Randomized Trial of Accelerated Re-Epithelization of Skin Graft Donor Sites Using Extracorporeal Shock Wave Therapy,” was chosen as a lead article in the journal and published July 14, 2010. It focused on the effect of SoftWave therapy on skin graft sites. Authored by Drs. Alexander Stojadinovic, Wolfgang Schaden, Richard Thiele, Christian Ottoman, Bernd Hartmann, Josh Tyler, and Heike Maier, the study found significant acceleration of donor site epithelization resulting from unfocused SoftWave treatment following skin graft harvest. Subjects receiving SoftWave therapy had mean epithelization times of 13.9 ± 2.0 days while those subjects not receiving SoftWave therapy had mean times of 16.7 ± 2.0 days. This represents a 16.8 percent improvement in mean healing time after one treatment. John Warlick, Chief Executive Officer of TRT, noted the significance of this peer-reviewed publication. “The percent reduction in healing time demonstrated in this randomized and controlled trial is highly significant both statistically and clinically,” Warlick also elaborated on the effects such a study has on TRT. “TRT's proprietary SoftWave technology offers clear cost and effectiveness advantages over competitive platforms by improving healing rates while reducing dependence on costly necessities such as anesthesia,” TRT was founded in 2005 to develop unfocused SoftWave technology in wound care and orthopedics and has since expanded its operations to the urology, cardiology, dental and neurological fields. Research has proven that unfocused SoftWave therapy has a strong regenerative effect on all avascular (scar) tissues by stimulating strong biologic responses. The biologic responses include production of growth factors, nitric oxide, and critical gene expressions, which results in angiogenesis and improve blood supply with strong antibacterial properties for treated areas. Conditions that benefit from shock wave treatment include acute and chronic wounds, non-healing bones, ischemic heart tissue, prostatitis and burns. The company currently sponsors U.S. Food and Drug Administration trials for its “Gold” product line, which is approved in Europe, Asia, Canada and South America. TRT is confident its technologies will dramatically improve patient care and reduce health care costs. Notice: This press release contains forward-looking statements within the meaning of the federal security laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements. TRT’s SoftWave technology is undergoing investigational use in the United States and is not currently available for sale. End
Account Email Address Disclaimer Report Abuse
|
|